Förderzeitraum 2020
Refine
Has Fulltext
- yes (23)
Is part of the Bibliography
- yes (23) (remove)
Document Type
- Journal article (23)
Language
- English (23)
Keywords
- multiple myeloma (5)
- relapse (3)
- B cells (2)
- inflammation (2)
- management (2)
- refractory (2)
- 18F-FDG PET/CT (1)
- AKT-signaling (1)
- ASE formula (1)
- Adaptive cell transfer (1)
- Autologous hematopoietic stem cell transplantation (1)
- CAR T cell (1)
- CCL3 (1)
- CCL4 (1)
- CCL5 (1)
- CCS (1)
- CD38 (1)
- CMV reactivation (1)
- Coronavirus Disease 2019 (1)
- Donor lymphocytes (1)
- HGF (1)
- HNSCC (1)
- Infectious complications (1)
- JCV (1)
- KRAS (1)
- MEK/ERK-signaling (1)
- MOR202 (1)
- MYC (1)
- Met (1)
- Myeloma (1)
- PD-L1 (1)
- PML (1)
- Pom‐PAD‐Dara (1)
- Prodigy (1)
- Radiochemotherapy (1)
- Rectal cancer (1)
- Severe Acute Respiratory Syndrome Coronavirus 2 (1)
- Surgery (1)
- Systemic sclerosis (1)
- T cells (1)
- Tdp-43 (1)
- Teichholz formula (1)
- Time interval (1)
- VLA-1 (1)
- acute graft-versus-host disease (1)
- acute respiratory distress syndrome (1)
- adalimumab (1)
- alloreactive T cells (1)
- amplicon sequencing (1)
- amyotrophic lateral sclerosis (1)
- anticoagulation (1)
- antithrombotic therapy (1)
- atrial fibrillation (1)
- autoimmune encephalitis (1)
- autoimmunity (1)
- autologous stem cell transplantation (1)
- axonal transcriptome (1)
- binding (1)
- bridging (1)
- capture (1)
- clinical trial (1)
- common variable immunodeficiency (1)
- complications (1)
- corticosteroids (1)
- cytokines (1)
- daratumumab (1)
- definition (1)
- discharge definition (1)
- echocardiography (1)
- fluorescence (1)
- gene (1)
- growth differentiation factor 15 (1)
- head and neck cancer (1)
- helicase (1)
- hemodialysis (1)
- homing (1)
- immune response (1)
- immune therapy (1)
- immunity (1)
- immunotherapeutics (1)
- immunotherapy (1)
- inflammation-induced tissue demage (1)
- interacts (1)
- kinease (1)
- left ventricular hypertrophy (1)
- left ventricular mass index (1)
- low molecular heparin (1)
- lymphocytes (1)
- memory B cells (1)
- mortality (1)
- mouse models (1)
- myeloid-derived suppressor cells (MDSCs) (1)
- natural killer cell (1)
- nicotinamide (1)
- nuclear receptors (1)
- nucleotide excision repair (1)
- oral anticoagulants (1)
- pancreatectomy (1)
- pathophysiology (1)
- pattern (1)
- postoperative bleeding (1)
- prediction (1)
- primary immunodeficiencies (1)
- progression (1)
- radiogenomics (1)
- recognition (1)
- rheumatoid arhritis (1)
- spleen (1)
- stem cell transplantation (1)
- subunit (1)
- sulfur (1)
- superior (1)
- surgical care (1)
- t-lymphocytes (1)
- thromboembolism (1)
- tocilizumab (IL-6 inhibitor) (1)
- toxicity (1)
- transactivation (1)
- transplantation (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- warfarin interruption (1)
Institute
- Medizinische Klinik und Poliklinik II (23) (remove)
Memory B cells have known to play an important role in the pathogenesis of rheumatoid arthritis (RA). With the emergence of B cell-targeted therapies, the modulation of memory B cells appears to be a key therapeutic target. Human peripheral memory B cells can be distinguished based on the phenotypic expression of CD27 and IgD, characterizing the three major B cell subpopulations: CD27+IgD+ pre-switch, CD27+IgD- post-switch, and CD27-IgD- double-negative memory B cells. We evaluated different memory cell populations for activation markers (CD95 and Ki-67) and chemokine receptors (CXCR3 and 4) expressing B cells in active RA, as well as under IL6-R blockade by tocilizumab (TCZ) and TNF-α blockade by adalimumab (ADA). Memory B cells were phenotypically analyzed from RA patients at baseline, week 12, and week 24 under TCZ or ADA treatment, respectively. Using flow cytometry, surface expression of CD95, intracellular Ki-67, and surface expressions of CXCR3 and CXCR4 were determined. Compared with healthy donors (n = 40), the phenotypic analysis of RA patients (n = 80) demonstrated that all three types of memory B cells were activated in RA patients. Surface and intracellular staining of B cells showed a significantly higher percentage of CD95+ (p < 0.0001) and Ki-67+ (p < 0.0001) cells, with numerically altered CXCR3+ and CXCR4+ cells in RA. CD95 and Ki-67 expressions were highest in post-switch memory B cells, whereas CD19+CXCR3+ and CD19+CXCR4+ expressing cells were substantially higher in the pre-switch compartment. In all subsets of the memory B cells, in vivo IL-6R, and TNF-α blockade significantly reduced the enhanced expressions of CD95 and Ki-67. Based on our findings, we conclude that the three major peripheral memory B cell populations, pre-, post-switch, and double-negative B cells, are activated in RA, demonstrating enhanced CD95 and Ki-67 expressions, and varied expression of CXCR3 and CXCR4 chemokine receptors when compared with healthy individuals. This activation can be efficaciously modulated under cytokine inhibition in vivo.
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines
(2020)
Approximately 20% of multiple myeloma (MM) cases harbor a point mutation in KRAS. However, there is still no final consent on whether KRAS-mutations are associated with disease outcome. Specifically, no data exist on whether KRAS-mutations have an impact on survival of MM patients at diagnosis in the era of novel agents. Direct blockade of KRAS for therapeutic purposes is mostly impossible, but recently a mutation-specific covalent inhibitor targeting KRAS\(^{p.G12C}\) entered into clinical trials. However, other KRAS hotspot-mutations exist in MM patients, including the less common exon-4 mutations. For the current study, the coding regions of KRAS were deep-sequenced in 80 newly diagnosed MM patients, uniformely treated with three cycles of bortezomib plus dexamethasone and cyclophosphamide (VCD)-induction, followed by high-dose chemotherapy and autologous stem cell transplantation. Moreover, the functional impact of KRAS\(^{p.G12A}\) and the exon-4 mutations p.A146T and p.A146V on different survival pathways was investigated. Specifically, KRAS\(^{WT}\), KRAS\(^{p.G12A}\), KRAS\(^{p.A146T}\), and KRAS\(^{p.A146V}\) were overexpressed in HEK293 cells and the KRAS\(^{WT}\) MM cell lines JJN3 and OPM2 using lentiviral transduction and the Sleeping Beauty vector system. Even though KRAS-mutations were not correlated with survival, all KRAS-mutants were found capable of potentially activating MEK/ERK- and sustaining PI3K/AKT-signaling in MM cells.
Common variable immunodeficiency (CVID) is the most common primary immunodeficiency in adults. It is associated with hypogammaglobulinemia, recurring infections and autoimmune phenomena. Treatment includes immunoglobulin substitution and immunosuppressants. Autoimmune neurological manifestations of CVID are rare and occur predominantly as granulomatous disease. We report the case of a 35-year-old woman with CVID who developed autoimmune encephalitis as demonstrated by double cerebral biopsy. Infectious or malignant causes could be excluded. Despite intensive immunosuppressive therapy with common regimens no significant improvement could be achieved. Ultimately, an autologous hematopoietic stem cell transplantation (HSCT) was performed, resulting in lasting complete remission of the encephalitis. To our knowledge, this is the first report of refractory autoimmune phenomena in CVID treated by autologous HSCT.